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Summary
Objective: To examine the deposition and pharmacokinetics of ciclesonide adminis-
tered via hydrofluoroalkane-metered dose inhaler (HFA-MDI) in patients with asthma.
Methods: Twelve patients with mild asthma (FEV1, 95% predicted) inhaled a single
dose of 99mtechnetium (Tc)-ciclesonide 320 mg ex-actuator (400 mg ex-valve).
Deposition of ciclesonide in the lung and oropharynx was quantified using two-
dimensional (2D)-gamma scintigraphy. Three-dimensional single photon emission
computed tomography (3D SPECT) was used to assess the regional distribution ofee front matter & 2005
med.2005.09.027
ng author. Tel.: +49 753
ess: anton.drollmann@aciclesonide in the lung. The pharmacokinetics of ciclesonide and its active
metabolite, desisobutyryl-ciclesonide (des-CIC), were determined by liquid chro-
matography-tandem mass spectrometry. Ciclesonide and des-CIC concentrations
were determined in mouth-rinsing solutions.
Results: 2D-gamma scintigraphy indicated that ciclesonide deposition was higher in
the whole lung (52%) than in the oropharynx (32.9%). Furthermore, 3D SPECT
revealed that ciclesonide deposition within the lungs was highest in the peripheral
regions that contain the small airways and alveoli. The pharmacokinetic profile of Tc-
labeled ciclesonide and des-CIC was similar to that obtained after inhalation of non-
labeled formulations in previous studies. Des-CIC accounted for 14.9% of the total
molar concentration of ciclesonide/des-CIC in mouth-rinsing solutions obtained
between 7 and 12min after inhalation.
Conclusion: Inhalation of ciclesonide via HFA-MDI results in high pulmonary
deposition, especially in the peripheral regions of the lung. High pulmonary deposition
contributes to ciclesonide’s ability to maintain lung function and control symptoms in
patients with asthma. Deposition and activation of ciclesonide in the oropharynx is
low, consistent with previous reports of low oropharyngeal deposition and a reduced
incidence of local side effects in patients receiving ciclesonide therapy.
& 2005 Published by Elsevier Ltd.Published by Elsevier Ltd.
1 84 2361; fax: +49 7531 84 92361.
ltanapharma.com (A. Drollmann).
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S. Newman et al.376IntroductionAsthma, one of the most common chronic diseases,
results from complex interactions among inflam-
matory cells, mediators, and the tissues and
cells in the airways and is characterized by
airway obstruction, airway inflammation, and air-
way hyperresponsiveness.1 Inhaled corticosteroids
(ICS) are the most effective agents available to
treat inflammation associated with mild asthma.1
The reduction in chronic airway inflammation
produced by ICS results in improved pulmonary
function.2 However, treatment with ICS may
cause local and systemic side effects, such as
reduction of bone formation, reduction of growth
velocity in children, skin bruising, and down-
regulation of endogenous cortisol release.3,4 There-
fore, ideally, systemic exposure to ICS should be
minimized.
Ciclesonide is a nonhalogenated ICS for the
treatment of asthma. Ciclesonide inhibits the
inflammatory response, including the activation
of lymphocytes and the infiltration of inflam-
matory cells into the airways.5 Clinical studies
show that ciclesonide significantly improves pul-
monary function and reduces airway hyperrespon-
siveness in patients with asthma.6,7 Ciclesonide is
delivered as an inactive parent compound to the
lungs, where it is converted by esterases to the
active metabolite, desisobutyryl-ciclesonide (des-
CIC). Subsequently, des-CIC is metabolized to
inactive metabolites in the liver by cytochrome
P-450 enzymes.8
Because ciclesonide and des-CIC have almost no
oral bioavailability,9 the pharmacokinetics (PK)
of ciclesonide in serum depends largely on pulmon-
ary deposition. Ciclesonide is administered as an
aerosol using a hydrofluoroalkane-134a metered-
dose inhaler (HFA-MDI). In a previous study, more
than 50% of the administered dose of ciclesonide
was deposited in the lungs of healthy volunteers.10
However, deposition of ciclesonide in the lung
may be impaired by the inflammation of the
small airways in patients with asthma. Bronchial
obstruction is also a determinant of aerosol
distribution within the lungs of asthma patients,
and increased bronchial obstruction enhances
central airway deposition of inhaled particles.11
For example, inhaled budesonide is more
centrally deposited in the lung in patients
with asthma than in healthy volunteers.12,13 The
current study investigated pulmonary deposition
of ciclesonide in patients with mild asthma.
Furthermore, this study assessed serum PK
and oropharyngeal deposition of ciclesonide and
des-CIC.Methods
Patients
Male and female patients with clinical symptoms of
asthma, a forced expiratory volume in 1 s (FEV1)
X80% predicted, and an FEV1/forced vital capacity
(FVC) ratio ofo0.85 were eligible to participate in
this study. Eligible patients were between the ages
of 18 and 65 years, of normal weight (Broca index:
0.80pweight/[height–100]p1.25), and were non-
smokers. Patients could receive anti-asthma med-
ication administered according to the same
schedule throughout the study and/or short-acting
beta (b)-agonists as rescue medication until 4 h
before ciclesonide inhalation.
Patients with a clinically active disease other
than asthma, clinically relevant allergies, hoarse-
ness or oropharyngeal candidiasis, upper respira-
tory tract infection within 14 days of the first study
day, or a lower respiratory tract infection within
the last 3 months were not eligible to participate in
this study. A negative drug test, negative hepatitis
test, and no history of drug or alcohol abuse were
also required. Women of childbearing age were
required to use an effective method of birth
control. The study was conducted at Pharmaceu-
tical Profiles Ltd. (Nottingham, UK) in accordance
with the revised Declaration of Helsinki and the
requirements of Good Clinical Practice.
Study design
This study had a single-dose, nonrandomized, open-
label design. Each patient received a single dose of
320 mg 99mTechnetium (Tc)-ciclesonide ex-actuator
(2 puffs of 160 mg; equivalent to 2 puffs of 200 mg
ex-valve). The primary study variable was the total
and regional distribution of ciclesonide in the lungs,
oropharynx, and exhaled air. Secondary variables
included the PK properties of ciclesonide and des-
CIC: area under the concentration curve from 0 to
infinity (AUC0inf), maximum serum concentration
(Cmax), terminal half-life (t1/2), time to reach
maximum concentration (tmax), and the concentra-
tion of ciclesonide and des-CIC in mouth-rinsing
solutions. Safety and tolerability of ciclesonide
were also assessed.
Radiolabeling of the ciclesonide formulation
A method for radiolabeling the ciclesonide formu-
lation using the radionuclide 99mTc was developed
and validated according to methodologies used in
previous studies in which deposition from an MDI
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Figure 1 Schematic representation of the shell analysis
system used to determine the regional distribution of
ciclesonide within the lung. The innermost shells (1 and
2) represent large central airways, whereas the outer-
most shells (5 and 6) represent the small peripheral
airways. Copyright& 2006 from Newman.18 Reproduced by
permission of Routledge/Taylor & Francis Group, LLC.
High lung deposition of ciclesonide 377was assessed.13,14 The radiolabeling method was
validated by comparing the size distributions of
ciclesonide and 99mTc in an Andersen cascade
impactor, operated at a flow rate of 28.3 L/min.
Administration of the radiolabeled
ciclesonide formulation
Patients inhaled 2 doses, approximately 1min
apart, of radiolabeled ciclesonide 160 mg (ex-
actuator, equivalent to 200 mg ex-valve) from an
MDI. Patients were instructed to inhale slowly and
deeply, and the MDI was actuated by an investigator
during inhalation. After inhaling, patients held
their breath for 10 s and then exhaled via a low-
resistance filter.
Measurement of lung function
Pulmonary function tests (FEV1, FVC, and peak
expiratory flow [PEF] rate) were performed at
screening, before dosing, at 1 and 14 h after dosing
on the study day, and at the poststudy visit. All
tests were performed using a MicroLoop Spirometer
(Micro Medical Ltd., Rochester, Kent, UK).
Scintigraphic assessment of lung deposition
Distribution of 99mTc-ciclesonide in the lungs,
oropharynx, esophagus, stomach, and exhaled air
was assessed using two-dimensional (2D) gamma
scintigraphy and three-dimensional single photon
emission computed tomography (3D SPECT) ima-
ging. Gamma scintigraphy was used to quantify the
total amount of drug deposited in the whole lung,
oropharynx, esophagus, stomach, and exhaled air
filter,14 whereas 3D SPECT imaging examined the
distribution of drug within the lungs in 3 dimen-
sions.15–17
Imaging was performed in the following se-
quence, using a Philips/ADAC Forte twin-headed
gamma camera coupled to a data-processing unit
(Philips Medical Systems, Surrey, UK): 2D-gamma
scintigraphy (anterior and posterior planar images
of the lungs and stomach, and lateral images of the
oropharynx immediately after dosing), 3D SPECT,
and repeat 2D-gamma scintigraphy of the lungs.
The planar lung images were corrected for the
effects of gamma ray attenuation by overlying
tissues. Planar lung images obtained before and
after SPECT imaging were compared to correct the
SPECT data for clearance of radiotracer from the
lungs into the systemic circulation. Patients were
supine with their arms above their heads during the
imaging procedure, which was completed within20–25min of their inhaling the radiolabeled drug
formulation. Either at the end of the 99mTc imaging
sequence or on a separate day, each patient
inhaled krypton-81m (81mKr) from a generator,
and the resulting ventilation scan was used to
obtain a 2D outline of the lungs.
Analysis of the 3D SPECT imaging focused on the
right lung to avoid possible artifacts caused by
heart and stomach overlap. To determine the
amount of ciclesonide deposited in regions contain-
ing airways of different sizes, the right lung was
divided into 6 concentric lung-shaped shells cen-
tered on the hilum (Fig. 1).18 Shell 1 represented
the innermost region of the lung and shell 6
represented the outermost (peripheral) region of
the lung. Shell thickness was calculated by dividing
the distance between the hilum and the lung
edge by 6. The lung edge was defined using data
acquired from a SPECT transmission scan using
gadolinium-153 (153Gd) line sources that are inte-
gral to the Philips/ADAC Forte gamma camera.
The count in each of the 6 concentric shells was
expressed as a percentage of the total right lung
count. These values were then multiplied by the
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Table 1 Patient demographics and baseline char-
acteristics.
Characteristic
Median age, years (range) 37 (23–50)
Median height, cm (range) 170 (163–188)
Median weight, kg (range) 77 (58–94)
Broca index (range) 1.05 (0.85–1.24)
Sex, n (%)
Male 7 (58)
Female 5 (42)
Smokers, n (%) 0 (0)
Nonsmokers, n (%) 12 (100)
FEV1 at screening
Measured, mean, L (SD) 3.41 (0.7)
% Predicted, mean (SD) 94.58 (7.5)
FEV1 ¼ Forced expiratory volume in 1 s; SD ¼ standard
deviation.
S. Newman et al.378mass of drug deposited in the right lung (obtained
from the planar 2D data) to determine the mass of
drug deposited per shell.
Blood sampling
Serial blood samples were collected predose and at
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and
14 h after dosing to determine des-CIC and cicleso-
nide PK. Approximately 8.5mL of blood was placed
in nonheparinized tubes and allowed to clot for
30min at 4 1C. Samples were centrifuged at 1550g
at 4 1C for 10min. The serum was transferred to
clean tubes, stored at 20 1C until the 99mTc
decayed to background levels, and analyzed by
liquid chromatography-tandem mass spectrometry
(LC-MS/MS).
Mouth-rinsing samples
Directly after oropharyngeal imaging (approxi-
mately 7–12min postdose), patients rinsed their
mouths by gargling twice with 30-mL aliquots of a
50% (v:v) ethanol:water solution. The mouth-
rinsing samples were combined and stored at
20 1C until 99mTc decayed to background levels,
and ciclesonide and des-CIC concentrations were
determined by LC-MS/MS. Immediately after the
mouth-rinsing procedure, patients rinsed their
mouths with 100mL mineral water.
Pharmacokinetic analysis of des-CIC and
ciclesonide
Serum and mouth-rinsing samples were analyzed at
MDS Pharma Services (Fehraltorf, Switzerland).
Ciclesonide and des-CIC were isolated from human
serum using solid-phase extraction; serum samples
(0.5mL) were diluted with 2mL 100mmol/L phos-
phate buffer (pH 2.8) and applied to solid-phase
extraction cartridges (Isolute C8; Phenomenex,
Cheshire, UK). Cartridges were washed twice with
50% methanol in water and the analytes were
eluted with 1mL acetonitrile, which was subse-
quently evaporated.
Ciclesonide and des-CIC concentrations were
determined using reversed-phase HPLC with MS/
MS detection. The limits of quantitation using
0.5mL of human serum were 10 pg/mL for des-CIC
and 25 pg/mL for ciclesonide. Assay precision
(coefficient of variation) was p8.4% for des-CIC
and p2.1% for ciclesonide. Deuterated ciclesonide
and des-CIC served as internal standards.
Des-CIC and ciclesonide concentrations were
determined in mouth-rinsing samples without sam-ple cleanup. Des-CIC was quantified by reversed-
phase HPLC with MS/MS detection. HPLC-MS/MS
assay precision was p1.3% for des-CIC, and the
limit of quantitation of des-CIC was 1 ng/mL using
0.2mL of mouth-rinsing sample. Deuterated des-
CIC served as internal standard. Ciclesonide was
quantified using LC-MS/MS analysis. Assay precision
was p2.5% for ciclesonide. Using 0.2mL of mouth-
rinsing solution, the limit of quantitation of
ciclesonide was 10 ng/mL.
Safety
Adverse events were recorded throughout the
study. Vital signs, 12-lead electrocardiogram, and
clinical chemistries were obtained before and after
the study.
Statistical analysis
Study variables, including the deposition of cicle-
sonide and the PK characteristics of ciclesonide and
des-CIC, were analyzed in a descriptive manner
using summary statistics such as mean and standard
deviation (SD). Pharmacokinetic analysis was per-
formed using KINTPC (ALTANA Pharma, version 2.1)
software.Results
Patient demographics
This study was conducted in 12 patients (7 male and
5 female) with mild asthma (Table 1). Mean FEV1 at
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Table 2 Lung function.
Variable Predose 1 h postdose 14 h postdose
FEV1
Measured, L 3.5070.80 3.4870.81 3.4370.72
% Predicted 97.25710.26 96.4278.44 95.5877.53
FVC, L 4.8471.11 4.8571.03 4.8071.01
PEF, L/s 8.3071.95 8.0771.70 8.2871.71
FEV1/FVC 0.7270.06 0.7270.04 0.7270.05
Data are presented as means7standard deviation (SD). N ¼ 12.
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Figure 2 Radiolabeling validation data showing the mean
distribution7SD of drug before labeling (n ¼ 3), drug
after labeling (n ¼ 4), and radiolabel (n ¼ 4) with an
Andersen cascade impactor. Stages of the impactor are as
follows: IP-MP ¼ inlet port-mouthpiece; S0–S7 ¼ stages
0–7; F ¼ final filter.
High lung deposition of ciclesonide 379baseline was approximately 95% predicted. The
median age was 37 years, and all patients were
nonsmokers and of normal weight. Each patient
completed the study without any relevant protocol
deviations.
Lung function
Lung function variables (FEV1, FVC, and PEF by
spirometry) remained stable in all patients
throughout the treatment period (Table 2).
Radiolabeling validation data
The distributions of drug before labeling, of drug
after labeling, and of radiolabel were similar
(Fig. 2). These results indicated that the radiola-
beling process did not change the particle size
distribution, and that the radiolabel was a satisfac-
tory marker for the drug in each particle size band.
The mean7SD fine particle fraction (percentage
recovered from stage 2 to final filter of the
Andersen cascade impactor) was 60.772.8% for
drug before labeling, 61.678.4% for drug after
labeling, and 61.578.7% for radiolabel. The valida-
tion data allowed the scintigraphic study to
proceed. The particle size distributions of each
inhaler used on study days were also assessed, and
the distributions of 99mTc within each particle size
band were similar to those tested before the study.
Deposition of ciclesonide
2D gamma scintigraphy indicated that a higher
percentage of the ex-actuator dose of ciclesonide
was deposited in the lungs (5279.0%) compared
with the oropharynx (32.9713.3%), esophagus
(6.273.8%), stomach (5.275.3%), and exhaled air
(3.773.1%) (Table 3; Fig. 3). Deposition in the right
lung accounted for 27.275.6% of the ex-actuator
dose (Table 4). Analysis of individual patient data
confirmed high deposition of ciclesonide in thelungs (Fig. 4). 3D SPECT revealed that the mean
deposition of ciclesonide was highest in the 2
outermost shells of the right lung, shell 5
(7.271.6% of the ex-actuator dose) and shell 6
(8.0%71.7% of the ex-actuator dose). Examination
of individual patient data further confirmed high
deposition of ciclesonide in the outermost shells of
the lung (Fig. 5). These shells are the ones most
likely to contain small airways and alveoli. Ex-
pressed on a mass basis, pulmonary deposition of
ciclesonide per puff was as follows: whole right
lung ¼ 43.679.0 mg; inner shells 1–4 ¼ 19.37
7.0 mg; and outer shells 5 and 6 ¼ 24.375.3 mg.
Although ciclesonide and des-CIC were both
present in patient mouth-rinsing solutions, activa-
tion of ciclesonide within the oropharynx was
low; the mean concentration7SD of ciclesonide
was 118.7757.0 mg/L (219.57105.5 nmol/L) and
des-CIC was 18.6713.0 mg/L (39.5727.5 nmol/L)
(Table 5). Therefore, des-CIC represented only
14.974.9% of the mean total molar concentration
of ciclesonide related metabolites in mouth-rinsing
solutions.
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Table 3 Two-dimensional gamma scintigraphy
analysis of the percentage distribution of cicleso-
nide 320 mg.
Site Mean
percentage
deposition7SD
Median
percentage
deposition
Whole lung 52.079.0 53.2
Oropharynx 32.9713.3 30.0
Esophagus 6.273.8 7.7
Stomach 5.275.3 3.6
Exhaled air 3.773.1 2.9
SD ¼ standard deviation.
Ex-actuator, equivalent to 400 mg ex-valve.
Figure 3 Two-dimensional planar imaging of the pattern
of ciclesonide deposition in the human body, with greatest
deposition occurring in the lung.
Table 4 3D SPECT analysis of the distribution of
99mTc-ciclesonide 160 mg in each of the 6 shells of
the right lung.
Shell Mass of
ciclesonide,
mean mg
per puff7SD
Ex-actuator
dose, mean
%7SD
Deposited
dose, %
1 0.370.3 0.270.2 0.7
2 2.971.3 1.870.8 6.7
3 7.372.8 4.571.8 16.7
4 8.872.6 5.571.6 20.2
5 11.572.6 7.271.6 26.4
6 12.872.7 8.071.7 29.4
Sum 43.579.0 27.275.6 100.0
3D SPECT ¼ 3-dimensional single photon emission com-
puted tomography; 99mTc ¼ 99mtechnetium; SD ¼ standard
deviation.
Shell 1 represents the innermost (central) region of the
lung; Shell 6 represents the outermost (peripheral) region
of the lung.
Ex-actuator (equivalent to 200 mg ex-valve). Patients
received a total dose of ciclesonide 320 mg ex-actuator
(equivalent to 400 mg ex-valve).
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Figure 4 Percent of ciclesonide deposition in the whole
lung, oropharynx, esophagus, stomach, and exhaled air
filter in 12 patients after inhalation of ciclesonide 320 mg
ex-actuator (equivalent to 400 mg ex-valve). Mean data
are presented as a solid line.
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In addition to the assessment of lung deposition, the
AUC(0inf), Cmax, Tmax, and t1/2 of ciclesonide and
des-CIC were determined. Serum levels of cicleso-
nide achieved a maximum concentration (Cmax) of
1.3670.53mg/L (mean7SD) at the first blood
sampling time point, 0.25 h after administration
(Tmax) (Table 6). The AUC(0inf) of ciclesonide was0.6870.26mg. h/L. Distribution and elimination
of ciclesonide were rapid with a mean t1/2 of
0.5770.08 h (Table 6; Fig. 6). The mean Cmax of
des-CIC (0.4170.11mg/L [mean7SD]), was achieved
approximately 0.9470.39 h after inhalation (Tmax).
Des-CIC had a mean elimination t1/2 of 6.0271.55 h
and an AUC(0inf) of 1.8770.66mg. h/L.
Safety
Ciclesonide 320 mg ex-actuator was safe and well
tolerated in this study. Three treatment-emergent
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Table 5 Concentration of ciclesonide and des-CIC
in mouth-rinsing solution after a single inhalation
of ciclesonide 320 mg.
Concentration Unit Mean7SD
Ciclesonide mg/L (nmol/L) 118.7757.0
(219.57105.5)
des-CIC mg/L (nmol/L) 18.6713.0
(39.5727.5)
Ciclesonide
plus des-CIC
nmol/L 259.07129.5
des-CIC (molar
basis)
% 14.974.9
SD ¼ standard deviation; des-CIC ¼ desisobutyryl-cicleso-
nide.
Ex-actuator (equivalent to 400 mg ex-valve).
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Figure 5 Percent of ciclesonide deposition in shells 1–6
of the lungs of 12 patients after inhalation of ciclesonide
320 mg ex-actuator (equivalent to 400 mg ex-valve). Mean
data are presented as a solid line.
Table 6 Pharmacokinetic characteristics of cicle-
sonide and des-CIC in serum after inhalation of a
single dose of ciclesonide 320 mg.
Pharmacokinetic
characteristic
Mean7SD
Ciclesonide des-CIC
AUC(0inf), mg. h/L 0.6870.26 1.8770.66
Cmax, mg/L 1.3670.53 0.4170.11
Tmax, h 0.2570.00 0.9470.39
t1/2, h 0.5770.08 6.0271.55
des-CIC ¼ desisobutyryl-ciclesonide; SD ¼ standard devia-
tion; AUC(0inf) ¼ area under the serum concentration-
time curve from 0 to infinity; Cmax ¼ maximum serum
concentration; Tmax ¼ time to maximum serum concen-
tration; t1/2 ¼ terminal half-life of des-CIC and distribu-
tion/elimination half-life of ciclesonide.
Ex-actuator (equivalent to 400 mg ex-valve).
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Figure 6 Mean (SEM) serum concentrations of ciclesonide
and the active metabolite, des-CIC, in 12 patients with
asthma after inhalation of ciclesonide 320 mg ex-actuator
(equivalent to 400 mg ex-valve). SEM ¼ standard error of
the mean; des-CIC ¼ desisobutyryl-ciclesonide.
High lung deposition of ciclesonide 381adverse events occurred in 2 patients; each of the 3
events was mild to moderate in intensity. One
patient reported peripheral swelling and altered
sensation of the left hand during the treatment
period, which was considered related to the
indwelling cannula. Another patient developed
mild nausea after inhalation of ciclesonide that
was considered ‘‘likely related’’ to the study drug.
Symptoms in both patients resolved after treat-
ment. There were no deaths, serious adverse
events, or study discontinuations due to adverse
events. In addition, there were no clinically
relevant changes in vital signs or clinical chemis-
tries during the study.Discussion
Gamma scintigraphy is a widely accepted method
used to assess lung deposition of inhaled sub-
stances.19 The reliability of this method depends on
adequate radiolabeling of the formulation. There-
fore, before this study was performed, labeled and
nonlabeled formulations were compared and there
was sufficient evidence that the radiolabel proce-
dure did not alter the particle size distribution of
the ciclesonide MDI. Moreover, the serum concen-
tration profiles of ciclesonide and des-CIC were
comparable with those obtained in a previous study
in which the same dose of nonlabeled ciclesonide
aerosol was administered to patients with mild
asthma.20 2D imaging allows overlap in the deposi-
tion of inhaled substances in large and small
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S. Newman et al.382airways. However, 3D SPECTeliminates this overlap
and enables the spatial distribution of the formula-
tion in the lung to be assessed more reliably.15
Distinguishing between lung compartments is of
relevance for the characterization of formulations
in which the targeting of distinct anatomic struc-
tures in the lung (e.g., peripheral airways) is
important for therapeutic effect.
This study demonstrated that more than 50% of
the ex-actuator dose of ciclesonide, delivered via
HFA-MDI, was deposited in the lungs of patients
with mild asthma. In addition, 3D SPECT imaging
revealed that the highest deposition of ciclesonide
within the lung occurred in the peripheral regions
that contain the small airways and alveoli. Patients
inhaled ciclesonide slowly and deeply during this
study, and distribution of radioactivity appeared to
be uniformly distributed in upper and lower lung
fields. In contrast, ciclesonide deposition within the
oropharynx accounted for 32.9% of the ex-actuator
dose. Furthermore, evaluation of mouth-rinsing
solutions showed that there was minimal conver-
sion of ciclesonide to des-CIC in the oropharynx.
The deposition and pharmacokinetics of cicleso-
nide were evaluated in 12 patients with asthma.
Scintigraphic studies typically involve between 8
and 12 subjects; therefore, a cohort of 12 patients
provides a valid estimate of mean ciclesonide
deposition and its variability between patients.
The results of this study are consistent with those
of a similar study conducted in 8 healthy volun-
teers.10 Similarly, deposition of beclomethasone
dipropionate from an HFA-MDI was higher in the
lungs compared with the oropharynx in 9 healthy
volunteers.21 A control group with another cicleso-
nide formulation was not employed in this study
only because the HFA-MDI formulation of cicleso-
nide is in development. Selective deposition of
ciclesonide in the lungs rather than the oropharynx
is a result of the formulation of ciclesonide and use
of the HFA-MDI as delivery device. Because of its
physicochemical properties, ciclesonide dissolves in
the carrier formulation used in the HFA-MDI and is
emitted as an aerosol of small particles, with a
mass median aerodynamic diameter of 1–2 mm,22
which are able to penetrate the narrow pulmonary
airways. High oropharyngeal deposition and low
lung deposition are usually observed for MDI
products in which the drug is formulated as a
suspension of micronized particles. For instance,
approximately 75–90% of CFC-MDI-delivered fluti-
casone propionate and beclomethasone dipropio-
nate, respectively, are deposited in the
oropharynx, and the majority of the ICS that
reaches the lung may be deposited in the central
airways with little peripheral penetration.21,23Mometasone furoate, administered via an HFA-227
MDI, achieves lung deposition of 7–25%.24 An HFA-
MDI formulation of beclomethasone dipropionate
has been shown to produce higher pulmonary
deposition and lower oropharyngeal deposition
than a formulation of micronized particles sus-
pended in chlorofluorocarbon propellants.23 Beclo-
methasone dipropionate was converted to the
active metabolite, beclomethasone monopropio-
nate, in precision-cut slices of rat lung, and 490%
of beclomethasone monopropionate was further
metabolized to pharmacologically inactive beclo-
methasone.25
High pulmonary deposition of ciclesonide,
coupled with its localization in the peripheral
regions of the lung as demonstrated in the present
study, probably contributes to the ability of this ICS
to maintain lung function, asthma symptom scores,
and rescue medication use in patients with mild
asthma.7 Furthermore, des-CIC possesses addi-
tional properties—high affinity for the glucocorti-
costeroid receptor, high lipophilicity, and lipid
conjugation—that promote retention of this ICS
within the lung and sustained anti-inflammatory
activity.5,25 These properties combine to produce
an ICS that, when administered as a once-daily
dose, provides effective control of mild asthma.7
Oropharyngeal deposition of an ICS can result in
local side effects such as oral candidiasis, dyspho-
nia, and pharyngitis.26,27 Although this study
showed that 32.9% of the ex-actuator dose of
ciclesonide was deposited in the oropharynx,
oropharyngeal activation of ciclesonide was low
because less than 15% of the deposited material
recovered in mouth-rinsing solutions corresponded
to des-CIC. This is consistent with previous reports
that oropharyngeal deposition of ciclesonide is
lower than that of budesonide or fluticasone
propionate.28,29
In addition, ICS deposited in the oropharynx may
be swallowed with saliva and absorbed from the
gastrointestinal tract into the systemic circulation
and, thereby, contribute to the development of
systemic side effects such as osteoporosis, growth
retardation, skin bruising and thinning, and catar-
acts.4 Older ICS such as beclomethasone dipropio-
nate and triamcinolone acetonide demonstrate
substantial systemic absorption from the gut.30
However, PK properties such as low oral bioavail-
ability, high protein binding, and high hepatic
clearance9,31,32 contribute to reduced systemic
exposure and the improved safety profile of
ciclesonide.33,34 In a recent study, the incidence
of oral candidiasis, hoarseness, and pharyngitis in
ciclesonide-treated patients was comparable with
placebo and lower than fluticasone propionate.27 In
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studies demonstrated that the incidence of oro-
pharyngeal side effects was similar to placebo and
lower than fluticasone propionate 880 mg in pa-
tients treated with ciclesonide (up to 640 mg
per day).35
In conclusion, this study reports that high
deposition and peripheral distribution of cicleso-
nide in the lung is achieved using an HFA-MDI.
Similar results were observed in healthy subjects,10
suggesting that changes that occur in the pulmon-
ary airways of patients with mild asthma have a
minimal effect upon the lung deposition of cicle-
sonide. Furthermore, reduced oropharyngeal de-
position, coupled with minimal activation in the
oropharynx, may contribute to the reduced inci-
dence of side effects associated with ciclesonide
use. Finally, although the present study was
conducted in patients with asthma, these patients
only had a mild form of the disease, as evidenced
by their near-normal lung function. Future studies
should be undertaken to determine whether cicle-
sonide deposition patterns are similar in patients
with moderate or severe asthma.References
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